263 related articles for article (PubMed ID: 2846699)
21. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues.
Colquhoun SD; Economou JS; Shau H; Golub SH
J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167
[TBL] [Abstract][Full Text] [Related]
22. Low deformability of lymphokine-activated killer cells as a possible determinant of in vivo distribution.
Sasaki A; Jain RK; Maghazachi AA; Goldfarb RH; Herberman RB
Cancer Res; 1989 Jul; 49(14):3742-6. PubMed ID: 2500233
[TBL] [Abstract][Full Text] [Related]
23. [Strategy of cancer treatment using human recombinant interleukin 2 and lymphokine activated killer cells].
Saijo N; Ozaki A; Ishihara J; Sakurai M; Sasaki Y; Takahashi H; Sano T; Hoshi A
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1290-7. PubMed ID: 3488026
[TBL] [Abstract][Full Text] [Related]
24. Interleukin 2 (IL 2) up-regulates its own receptor on a subset of human unprimed peripheral blood lymphocytes and triggers their proliferation.
Harel-Bellan A; Bertoglio J; Quillet A; Marchiol C; Wakasugi H; Mishall Z; Fradelizi D
J Immunol; 1986 Apr; 136(7):2463-9. PubMed ID: 3005412
[TBL] [Abstract][Full Text] [Related]
25. Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2.
Rosenstein M; Yron I; Kaufmann Y; Rosenberg SA
Cancer Res; 1984 May; 44(5):1946-53. PubMed ID: 6608989
[TBL] [Abstract][Full Text] [Related]
26. Identification and selection of human lymphokine activated killer cell effectors and novel recycling intermediates by unique light-scattering properties.
Loudon WG; Abraham SR; Owen-Schaub LB; Hemingway LL; Hemstreet GP; DeBault LE
Cancer Res; 1988 Apr; 48(8):2184-92. PubMed ID: 3258186
[TBL] [Abstract][Full Text] [Related]
27. Limiting dilution analysis of the frequency of human T cells and large granular lymphocytes proliferating in response to interleukin 2. I. The effect of lectin on the proliferative frequency and cytotoxic activity of cultured lymphoid cells.
Vose BM; Bonnard GD
J Immunol; 1983 Feb; 130(2):687-93. PubMed ID: 6600251
[TBL] [Abstract][Full Text] [Related]
28. Adherent lymphokine-activated natural killer cells in normal and severe combined immunodeficiency mice: large granular lymphocytes with natural killer cell phenotype and high cytolytic activity.
Chang HL; Zaroukian MH; Morrison MH; Esselman WJ
Nat Immun Cell Growth Regul; 1989; 8(2):89-99. PubMed ID: 2788243
[TBL] [Abstract][Full Text] [Related]
29. A new approach to generating antitumor effectors for adoptive immunotherapy using human adherent lymphokine-activated killer cells.
Melder RJ; Whiteside TL; Vujanovic NL; Hiserodt JC; Herberman RB
Cancer Res; 1988 Jun; 48(12):3461-9. PubMed ID: 3259468
[TBL] [Abstract][Full Text] [Related]
30. Changes in homing receptor expression on murine lymphokine-activated killer cells during IL-2 exposure.
Steen PD; McGregor JR; Lehman CM; Samlowski WE
J Immunol; 1989 Dec; 143(12):4324-30. PubMed ID: 2687380
[TBL] [Abstract][Full Text] [Related]
31. The expression and functional involvement of laminin-like molecules in non-MHC restricted cytotoxicity by human Leu-19+/CD3- natural killer lymphocytes.
Schwarz RE; Hiserodt JC
J Immunol; 1988 Nov; 141(10):3318-23. PubMed ID: 3263421
[TBL] [Abstract][Full Text] [Related]
32. Natural killer (NK) cell activity in the rat. I. Isolation and characterization of the effector cells.
Reynolds CW; Timonen T; Herberman RB
J Immunol; 1981 Jul; 127(1):282-7. PubMed ID: 7240744
[TBL] [Abstract][Full Text] [Related]
33. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
[TBL] [Abstract][Full Text] [Related]
34. Differential expression of lymphokine-activated killer cells and natural killer cells in adoptive transfer experiments utilizing fractionated bone marrow.
Merluzzi VJ; Trail PA; Last-Barney K
J Immunol; 1986 Oct; 137(8):2425-7. PubMed ID: 3531332
[TBL] [Abstract][Full Text] [Related]
35. Generation of lymphokine-activated killer cells in strain 2 guinea pigs and their use in the therapy of L2C, an acute B-cell leukemia.
Gregg EO; Gregg IC; Green I
Cancer Res; 1987 Feb; 47(3):723-9. PubMed ID: 3492265
[TBL] [Abstract][Full Text] [Related]
36. Lysis of fresh human tumor cells by autologous large granular lymphocytes and T-lymphocytes: two distinct killing activities induced by coculture with autologous tumor.
Uchida A; Moore M
J Natl Cancer Inst; 1984 Dec; 73(6):1285-92. PubMed ID: 6239944
[TBL] [Abstract][Full Text] [Related]
37. Precursor phenotype of lymphokine-activated killer cells in the mouse.
Salup RR; Mathieson BJ; Wiltrout RH
J Immunol; 1987 Jun; 138(11):3635-9. PubMed ID: 3108370
[TBL] [Abstract][Full Text] [Related]
38. Effects of natural and recombinant IL 2 on regulation of IFN gamma production and natural killer activity: lack of involvement of the Tac antigen for these immunoregulatory effects.
Ortaldo JR; Mason AT; Gerard JP; Henderson LE; Farrar W; Hopkins RF; Herberman RB; Rabin H
J Immunol; 1984 Aug; 133(2):779-83. PubMed ID: 6203980
[TBL] [Abstract][Full Text] [Related]
39. Interleukin 2 induces human acute lymphocytic leukemia cells to manifest lymphokine-activated-killer (LAK) cytotoxicity.
Kaufmann Y; Levanon M; Davidsohn J; Ramot B
J Immunol; 1987 Aug; 139(3):977-82. PubMed ID: 3496395
[TBL] [Abstract][Full Text] [Related]
40. Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2.
Ettinghausen SE; Rosenberg SA
Cancer Res; 1986 Jun; 46(6):2784-92. PubMed ID: 3486038
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]